Allena Pharmaceuticals, Inc. (ALNA)
Nur zu Informationszwecken. Keine Finanzberatung. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
ALNA steht fuer Allena Pharmaceuticals, Inc., ein Healthcare-Unternehmen mit einem Kurs von $ (Marktkapitalisierung 0).
Zuletzt analysiert: 17. März 2026Allena Pharmaceuticals, Inc. (ALNA) Gesundheitswesen & Pipeline-Uebersicht
Allena Pharmaceuticals, Inc. is a biotechnology firm specializing in oral enzyme therapeutics for rare metabolic and kidney disorders, with ALLN-346 as its primary focus. The company operates within the competitive biotechnology sector, addressing unmet needs in chronic kidney disease and related conditions.
Investmentthese
Allena Pharmaceuticals, Inc. presents a focused investment opportunity within the biotechnology sector, driven by its lead product candidate, ALLN-346, targeting hyperuricemia and gout in advanced chronic kidney disease patients. The potential for ALLN-346 to address a significant unmet need in this patient population is a key value driver. The company's success hinges on positive clinical trial outcomes and subsequent regulatory approval. Key risks include clinical trial failures, regulatory hurdles, and competition from existing and emerging therapies. With a P/E ratio of -0.07 and a beta of 1.15, the company reflects the inherent volatility and speculative nature of biotechnology investments. The absence of a dividend underscores the company's focus on reinvesting earnings into research and development.
Basierend auf FMP-Finanzdaten und quantitativer Analyse
Wichtige Highlights
- Lead product candidate ALLN-346 targets hyperuricemia and gout in advanced chronic kidney disease patients.
- Focus on oral enzyme therapeutics offers a potentially convenient treatment option.
- Strategic focus on rare and severe diseases allows for targeted patient populations and potential market exclusivity.
- Incorporated in 2011, indicating a relatively young company in the biotechnology space.
- Headquartered in Newton, Massachusetts, a hub for biotechnology and pharmaceutical companies.
Wettbewerber & Vergleichsunternehmen
Staerken
- Proprietary enzyme technology platform
- Lead product candidate targeting a specific unmet need
- Experienced management team
- Focus on rare and severe diseases
Schwaechen
- Limited financial resources
- Dependence on a single product candidate
- Small number of employees
- Lack of commercial infrastructure
Katalysatoren
- Upcoming: Clinical trial results for ALLN-346.
- Upcoming: Potential regulatory approval of ALLN-346.
- Ongoing: Strategic partnerships and collaborations.
- Ongoing: Expansion into new therapeutic areas.
Risiken
- Potential: Clinical trial failures.
- Potential: Regulatory hurdles.
- Potential: Competition from existing therapies.
- Ongoing: Limited financial resources.
- Ongoing: Dependence on a single product candidate.
Wachstumschancen
- Expansion into New Therapeutic Areas: Allena Pharmaceuticals, Inc. can leverage its expertise in enzyme therapeutics to expand into new therapeutic areas beyond hyperuricemia and gout. This could involve developing novel enzyme-based therapies for other metabolic or kidney disorders with unmet medical needs. The market size for enzyme replacement therapies is projected to reach billions of dollars in the coming years, presenting a significant growth opportunity for Allena. Timeline: 3-5 years.
- Geographic Expansion: Allena Pharmaceuticals, Inc. can expand its geographic reach beyond the United States to target international markets with significant patient populations suffering from hyperuricemia and gout. This could involve establishing partnerships with international distributors or pursuing regulatory approvals in key markets such as Europe and Asia. The global market for gout treatment is expected to grow substantially, driven by increasing prevalence and aging populations. Timeline: 2-4 years.
- Strategic Partnerships and Collaborations: Allena Pharmaceuticals, Inc. can pursue strategic partnerships and collaborations with larger pharmaceutical companies or research institutions to accelerate the development and commercialization of its product candidates. This could involve licensing agreements, co-development partnerships, or joint ventures. Collaborations can provide access to additional resources, expertise, and market access. Timeline: Ongoing.
- Development of Next-Generation Enzyme Therapeutics: Allena Pharmaceuticals, Inc. can invest in the development of next-generation enzyme therapeutics with improved efficacy, safety, and delivery methods. This could involve engineering novel enzymes with enhanced catalytic activity or developing innovative oral delivery systems to improve bioavailability. The market for advanced drug delivery technologies is rapidly growing, driven by the need for more effective and convenient therapies. Timeline: 5+ years.
- Acquisition of Complementary Technologies or Companies: Allena Pharmaceuticals, Inc. can pursue strategic acquisitions of complementary technologies or companies to expand its product pipeline and capabilities. This could involve acquiring companies with expertise in enzyme engineering, drug delivery, or related therapeutic areas. Acquisitions can provide access to new technologies, intellectual property, and talent. Timeline: Opportunistic.
Chancen
- Expansion into new therapeutic areas
- Strategic partnerships and collaborations
- Geographic expansion
- Favorable regulatory environment for orphan drugs
Risiken
- Clinical trial failures
- Regulatory hurdles
- Competition from existing therapies
- Patent expiration
Wettbewerbsvorteile
- Proprietary enzyme technology
- Patent protection for ALLN-346
- Focus on rare and severe diseases
- Specialized expertise in enzyme therapeutics
Ueber ALNA
Allena Pharmaceuticals, Inc., founded in 2011 and headquartered in Newton, Massachusetts, is a biopharmaceutical company dedicated to discovering, developing, and commercializing oral enzyme therapeutics. The company focuses on addressing unmet needs in patients with rare and severe metabolic and kidney disorders. Allena's lead product candidate, ALLN-346, is a novel, orally administered enzyme designed to degrade urate in the gastrointestinal tract. This therapeutic approach aims to reduce the burden of hyperuricemia and gout, particularly in individuals with advanced chronic kidney disease (CKD). The company's research and development efforts are centered on enzyme-based therapies that can be administered orally, offering a convenient and potentially more effective treatment option for patients with these debilitating conditions. Allena's strategic focus on rare and severe diseases allows it to target specific patient populations with significant unmet medical needs, potentially leading to accelerated regulatory pathways and market exclusivity. The company's operations are currently based in the United States, with a focus on clinical development and eventual commercialization of its lead product candidate.
Was das Unternehmen tut
- Discovers oral enzyme therapeutics
- Develops oral enzyme therapeutics
- Commercializes oral enzyme therapeutics
- Treats patients with rare metabolic disorders
- Treats patients with severe metabolic disorders
- Treats patients with rare kidney disorders
- Treats patients with severe kidney disorders
Geschaeftsmodell
- Develops and patents novel enzyme therapeutics.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from the FDA.
- Commercializes approved products through sales and marketing efforts.
Branchenkontext
Allena Pharmaceuticals, Inc. operates within the biotechnology industry, a sector characterized by high innovation, significant regulatory hurdles, and substantial investment in research and development. The company's focus on rare and severe metabolic and kidney disorders positions it within a niche market with potentially less competition but also smaller patient populations. The biotechnology industry is driven by advancements in genomics, proteomics, and other areas of biological science, leading to the development of novel therapies for previously untreatable diseases. The competitive landscape includes both large pharmaceutical companies and smaller biotechnology firms, all vying for market share in various therapeutic areas.
Wichtige Kunden
- Patients with hyperuricemia and gout
- Patients with advanced chronic kidney disease
- Healthcare providers treating these patients
- Pharmacies dispensing the medication
Finanzdaten
Chart & Info
Allena Pharmaceuticals, Inc. (ALNA) Aktienkurs: Price data unavailable
Aktuelle Nachrichten
-
Stocks That Hit 52-Week Lows On Tuesday
benzinga · 26. Apr. 2022
-
Stocks That Hit 52-Week Lows On Friday
· 8. Nov. 2019
-
Stocks That Hit 52-Week Lows On Wednesday
· 2. Okt. 2019
-
Stocks That Fell Through 52-Week Lows Wednesday
· 7. Aug. 2019
Analystenkonsens
Konsens-Bewertung
Aggregierte Kauf-/Halten-/Verkauf-Empfehlungen von Benzinga, Yahoo Finance und Finnhub fuer ALNA.
Kursziele
Wall-Street-Kurszielanalyse fuer ALNA.
MoonshotScore
Was bedeutet diese Bewertung?
Der MoonshotScore bewertet das Wachstumspotenzial von ALNA auf einer Skala von 0-100 ueber mehrere Faktoren wie Innovation, Marktdisruption, finanzielle Gesundheit und Momentum.
Wettbewerber & Vergleichsunternehmen
Fuehrung: Louis Brenner
CEO
Louis Brenner serves as the Chief Executive Officer of Allena Pharmaceuticals, Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on corporate strategy, business development, and commercialization. Prior to joining Allena, he held leadership positions at various biotechnology and pharmaceutical companies, where he was responsible for driving growth and innovation. He has a strong track record of building and managing successful teams, as well as executing strategic transactions.
Erfolgsbilanz: Under Louis Brenner's leadership, Allena Pharmaceuticals, Inc. has focused on advancing the clinical development of ALLN-346 and exploring strategic opportunities to expand its pipeline. Key milestones include initiating and completing clinical trials for ALLN-346 and securing funding to support the company's research and development efforts. He is managing 12 employees.
Haeufige Fragen zu ALNA
What are the key factors to evaluate for ALNA?
Evaluating ALNA involves reviewing fundamentals, analyst consensus, and risk factors. Key strength: Proprietary enzyme technology platform. Primary risk to monitor: Potential: Clinical trial failures.. This is not financial advice.
How frequently does ALNA data refresh on this page?
ALNA prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven ALNA's recent stock price performance?
Recent price movement in Allena Pharmaceuticals, Inc. (ALNA) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary enzyme technology platform. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider ALNA overvalued or undervalued right now?
Determining whether Allena Pharmaceuticals, Inc. (ALNA) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying ALNA?
Before investing in Allena Pharmaceuticals, Inc. (ALNA), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ALNA to a portfolio?
Potential reasons to consider Allena Pharmaceuticals, Inc. (ALNA) depend on individual investment goals and risk tolerance. A key strength identified by analysis: Proprietary enzyme technology platform. Additionally: Lead product candidate targeting a specific unmet need. Always weigh potential rewards against risks and diversify across holdings. This is not financial advice.
Can I buy fractional shares of ALNA?
Yes, most major brokerages offer fractional shares of Allena Pharmaceuticals, Inc. (ALNA) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ALNA's earnings and financial reports?
Allena Pharmaceuticals, Inc. (ALNA) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Setting up alerts through your brokerage for ALNA earnings announcements is recommended.
Haftungsausschluss: Dieser Inhalt dient ausschliesslich zu Informationszwecken und stellt keine Anlageberatung dar. Fuehren Sie immer Ihre eigene Recherche durch und konsultieren Sie einen Finanzberater.
Offizielle Ressourcen
Daten dienen ausschliesslich zu Informationszwecken.
- Information is based on available data as of 2026-03-17.
- AI analysis is pending, which may provide further insights.